MedTrace Logo

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)

NCT05366257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160602

Last updated 2022-07-05

No results posted yet for this study

Summary

A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with CAR-T therapy among patients with r/r Diffuse Large B-cell Lymphoma (DLBCL).

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

OTHER

CAR-T

infusion of CAR-T therapy among patients with r/r DLBCL

OTHER

Allo-HSCT cohort

Patients received allogeneic hematopoietic stem cell transplant

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2021-05-10
Completion
2021-05-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366257 on ClinicalTrials.gov